About
Developing Cures for Multiple Infectious Diseases
101 Therapeutics has developed the first-ever targeted glucocorticoid with all of the potency of steroids and none of the systemic toxicities. By targeting the host immune system rather than the pathogen itself, the company can effectively treat a multitude of infectious diseases, whether viral, parasitic, or bacterial.
Identity
| Name | 101 Therapeutics |
|---|---|
| Slug | 101-therapeutics |
| Type / kind | startup |
| Source _id | ed9xyj0h63HIc9SJLitlvgIgVLkN236OeC1jZT9nsB0Yo161DnsSA0 |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ city | Tel Aviv-Yafo |
| HQ address | Tel Aviv-Yafo, Israel |
Web & social
| Website | https://www.101therapeutics.com/ |
|---|---|
| https://www.linkedin.com/company/70077086 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
biotechnologypharmaceuticalsinfectious-diseasedrug-developmentdrug-discovery
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}